Caladrius Biosciences Quote - CLBS

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

0.4264

Bid

0.4264

Offer

0.43

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

3.475M

Previous Close

0.4264

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

8,150,000

Dividend Yield

PE Ratio

-1.18

Earnings Per Share (EPS)

-2.56

Revenue

Net Profit

-20.84M

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the... Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to the development of treatments and reversal of severe diseases. The company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. Its current product candidates include XOWNA, HONEDRA and CLBS201. Show more

Sector

Health & Allied Services,nec

Industry

Insurance Carriers, Nec

Website

www.caladrius.com

Headquarters

Wilmington, Delaware, USA

Founded

2006

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA” Lisata has approximately $76 million in cash and investments following transaction close Lisata strengthens...

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified...

Life Sciences Virtual Investor Conference Agenda Announced for September 15th

NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual...

Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022

BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing...

Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations Agreement accelerated by Caladrius’ initial...

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics Conference call begins...

Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

BASKING RIDGE, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative...

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology

BASKING RIDGE, N.J. and SAN DIEGO, July 06, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company...

Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group

BASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

CLBS - Frequently Asked Questions (FAQ)

What is the current Caladrius Biosciences share price?

The current share price of Caladrius Biosciences is US$ 0.4264

How many Caladrius Biosciences shares are in issue?

Caladrius Biosciences has 8,150,000 shares in issue

What is the market cap of Caladrius Biosciences?

The market capitalisation of Caladrius Biosciences is USD 3.48M

What is the 1 year trading range for Caladrius Biosciences share price?

Caladrius Biosciences has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Caladrius Biosciences?

The price to earnings ratio of Caladrius Biosciences is -1.18

What is the reporting currency for Caladrius Biosciences?

Caladrius Biosciences reports financial results in USD

What is the latest annual profit for Caladrius Biosciences?

The latest annual profit of Caladrius Biosciences is USD -20.84M

What is the registered address of Caladrius Biosciences?

The registered address for Caladrius Biosciences is 651 N BROAD ST SUITE 201, NEW CASTLE, WILMINGTON, DELAWARE, 19709

What is the Caladrius Biosciences website address?

The website address for Caladrius Biosciences is www.caladrius.com

Which industry sector does Caladrius Biosciences operate in?

Caladrius Biosciences operates in the INSURANCE CARRIERS, NEC sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
INTZIntrusion Inc	US$ 2.167 (381.56%)	189.59M
AILEiLearningEngines Inc	US$ 0.5932 (267.31%)	563.26M
HUBCWHub Cyber Security Ltd	US$ 0.035 (250.00%)	2.79M
GTIGraphjet Technology	US$ 0.967551 (185.83%)	398.95M
LITMSnow Lake Resources Ltd	US$ 1.61 (82.95%)	131.98M
NEUPNeuphoria Therapeutics Inc	US$ 4.11 (-92.30%)	936.47k
VIRXViracta Therapeutics Inc	US$ 0.16 (-32.49%)	9.31M
PRFXPainReform Ltd	US$ 3.48 (-28.98%)	926.19k
AIREreAlpha Tech Corporation	US$ 2.56 (-28.49%)	8.26M
AVGRAvinger Inc	US$ 0.9721 (-24.05%)	2.11M
AILEiLearningEngines Inc	US$ 0.5932 (267.31%)	557.72M
GTIGraphjet Technology	US$ 0.967551 (185.83%)	398.75M
RGTIRigetti Computing Inc	US$ 17.08 (10.62%)	298.47M
XTIAXTI Aerospace Inc	US$ 0.03935 (-1.63%)	263.01M
QSIQuantum Si Inc	US$ 3.585 (66.74%)	250.36M